<DOC>
	<DOCNO>NCT02106156</DOCNO>
	<brief_summary>This observational study examine efficacy safety pegylated interferon ( peginterferon ) alfa-2a , mostly combination ribavirin treatment chronic hepatitis C ( CHC ) . Quality care also assess . Approximately 12 % interferon-treated CHC patient population Germany expect studied period 5 year .</brief_summary>
	<brief_title>Observational Study Evaluating Quality Pegylated Interferon Alfa-2a Ribavirin Treatment Chronic Hepatitis C Cooperation With BNG ( Association German Resident Gastroenterologists )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>18 year age Clinically diagnose CHC detectable virus replication Women childbearing potential use adequate contraception . It important female participant childbearing potential sexual partner use 2 contraceptive method time treatment 4 month treatment discontinuation . During time pregnancy test perform monthly . Particular attention also required pregnancy avoid 7 month treatment discontinuation female sexual partner male participant take ribavirin ( CopegusÂ® ) . Both use adequate contraception . Any contraindication peginterferon alfa2a ribavirin treatment Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>